Filing Details

Accession Number:
0000899243-20-004522
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-13 18:30:38
Reporting Period:
2020-02-11
Accepted Time:
2020-02-13 18:30:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367644 Emergent Biosolutions Inc. EBS Pharmaceutical Preparations (2834) 141902018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380185 Fuad El-Hibri 400 Professional Drive, Suite 400
Gaithersburg MD 20879
Chairman Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-11 6,280 $25.62 1,485,298 No 4 M Direct
Common Stock Disposition 2020-02-11 6,280 $62.90 1,479,018 No 4 S Direct
Common Stock Acquisiton 2020-02-12 13,720 $25.62 1,492,738 No 4 M Direct
Common Stock Disposition 2020-02-12 13,720 $62.90 1,479,018 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (Right to Buy) Disposition 2020-02-11 6,280 $0.00 6,280 $25.62
Common Stock Employee Stock Options (Right to Buy) Disposition 2020-02-12 13,720 $0.00 13,720 $25.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
57,038 2021-03-10 No 4 M Direct
43,318 2021-03-10 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,344,250 Indirect By Intervac, L.L.C.
Common Stock 1,524,155 Indirect By Biovac, L.L.C.
Footnotes
  1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
  2. Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
  3. Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
  4. The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017.